

Cochrane Database of Systematic Reviews

Increasing antipsychotic dose versus switching antipsychotic for non response in schizophrenia (Review)

Samara MT, Klupp E, Helfer B, Rothe PH, Schneider-Thoma J, Leucht S

Samara MT, Klupp E, Helfer B, Rothe PH, Schneider-Thoma J, Leucht S. Increasing antipsychotic dose versus switching antipsychotic for non response in schizophrenia. *Cochrane Database of Systematic Reviews* 2018, Issue 5. Art. No.: CD011884. DOI: 10.1002/14651858.CD011884.pub2.

www.cochranelibrary.com



TABLE OF CONTENTS

HEADER	1
ABSTRACT	1
PLAIN LANGUAGE SUMMARY	2
SUMMARY OF FINDINGS	3
BACKGROUND	5
OBJECTIVES	6
METHODS	6
RESULTS	11
Figure 1 1	12
Figure 2	14
Figure 3	15
DISCUSSION	16
AUTHORS' CONCLUSIONS	17
ACKNOWLEDGEMENTS	17
REFERENCES 1	18
CHARACTERISTICS OF STUDIES	23
DATA AND ANALYSES	27
Analysis 1.1. Comparison 1 Increasing the antipsychotic dose versus switching the atipsychotic drug, Outcome 1 Global state: 2 clinically relevant response – as defined by trial.	27
Analysis 1.2. Comparison 1 Increasing the antipsychotic dose versus switching the atipsychotic drug, Outcome 2 Mental state: 2 general mental state - average endpoint score (BPRS total, high =poor).	27
Analysis 1.3. Comparison 1 Increasing the antipsychotic dose versus switching the atipsychotic drug, Outcome 3 Mental state: 2 negative symptoms - average endpoint score (SANS, high = poor).	28
ADDITIONAL TABLES	28
APPENDICES	29
CONTRIBUTIONS OF AUTHORS	29
DECLARATIONS OF INTEREST	30
SOURCES OF SUPPORT	30
DIFFERENCES BETWEEN PROTOCOL AND REVIEW	30
INDEX TERMS	30



[Intervention Review]

Increasing antipsychotic dose versus switching antipsychotic for non response in schizophrenia

Myrto T Samara¹, Elisabeth Klupp², Bartosz Helfer¹, Philipp H Rothe¹, Johannes Schneider-Thoma¹, Stefan Leucht¹

¹Klinik und Poliklinik für Psychiatrie und Psychotherapie, Technische Universität München Klinikum rechts der Isar, München, Germany. ²Department of Diagnostic and Interventional Neuroradiology, Klinikum rechts der Isar, Technical University Munich, München, Germany

Contact address: Stefan Leucht, Klinik und Poliklinik für Psychiatrie und Psychotherapie, Technische Universität München Klinikum rechts der Isar, Ismaninger Straße 22, München, 81675, Germany. Stefan.Leucht@lrz.tum.de.

Editorial group: Cochrane Schizophrenia Group. **Publication status and date:** New, published in Issue 5, 2018.

Citation: Samara MT, Klupp E, Helfer B, Rothe PH, Schneider-Thoma J, Leucht S. Increasing antipsychotic dose versus switching antipsychotic for non response in schizophrenia. *Cochrane Database of Systematic Reviews* 2018, Issue 5. Art. No.: CD011884. DOI: 10.1002/14651858.CD011884.pub2.

Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

ABSTRACT

Background

Many people with schizophrenia do not respond to an initially prescribed antipsychotic drug. In such cases, one treatment strategy could be to increase the antipsychotic dose; and another strategy could be to switch to a different antipsychotic drug.

Objectives

To examine the efficacy of increasing the antipsychotic dose versus switching the antipsychotic drug in the treatment of non-responsive people with schizophrenia.

Search methods

We searched the Cochrane Schizophrenia Group Trials Register (10 June 2014, 6 October 2015, and 30 March 2017). We examined references of all included studies for further trials.

Selection criteria

All relevant randomised controlled trials (RCTs) comparing increasing the antipsychotic dose versus switching to a different antipsychotic drug for people with schizophrenia who have not responded to their initial antipsychotic treatment.

Data collection and analysis

At least two review authors independently extracted data. We analysed dichotomous data using relative risks (RR) and their 95% confidence intervals (CIs). We analysed continuous data using mean differences (MD) and their 95% CIs. We assessed risk of bias for included studies and used GRADE to create a 'Summary of findings' table.

Main results

We include one RCT with relevant data on 29 participants in this review. The trial had a parallel design and was double-blind, but blinding procedures were not described. The trial included people who were non-responsive to fluphenazine 20 mg/day administered for 4 weeks. Participants were randomly assigned to continuing treatment with fluphenazine 20 mg/day, increasing the dose to fluphenazine 80 mg/day or switching to haloperidol 20 mg/day for four additional weeks. Data were reported only for 47 out of 58 initially randomised participants. The trial was published in 1993. The fact that only one RCT with a small sample size (N = 29) was included in the analysis limits the quality of the evidence. Overall, no clear difference was found between groups in terms of the three available outcomes: global state (number of participants with clinically relevant response (RR 1.63, 95% CI 0.17 to 15.99, *very low quality evidence*); general mental state (endpoint



score, BPRS total) (MD 2.00, 95% CI –4.20 to 8.20, *very low quality evidence*); and negative symptoms (endpoint score, SANS) (MD 3.40, 95% CI –12.56 to 19.36). No data were reported for leaving the study early, adverse effects, time in hospital, quality of life, satisfaction with care and functioning.

Authors' conclusions

There is extremely limited evidence and no clear conclusions can be drawn. There is an urgent need for further trials in order to determine the optimal treatment strategy for people with schizophrenia who do not respond to their initial antipsychotic treatment.

PLAIN LANGUAGE SUMMARY

Increasing antipsychotic dose versus switching to a different antipsychotic for people with schizophrenia who do not respond to initial treatment

Review question

If a person with schizophrenia does not initially respond to an antipsychotic, is increasing the dose of this antipsychotic more effective, and safer, compared with switching to another antipsychotic?

Background

Many people with the serious mental illness schizophrenia do not respond fully (i.e. symptoms such as delusions and hallucinations still remain) with a standard dose of an initially prescribed antipsychotic drug. In such cases, clinicians can consider increasing the antipsychotic dose beyond regular thresholds or switching to a different antipsychotic drug in order to enhance antipsychotic efficacy. The evidence surrounding the optimal treatment strategy is scarce.

Searching for evidence

The Information Specialist of Cochrane Schizophrenia ran an electronic search (up to 30 March 2017) for trials that randomised people with schizophrenia who were not responding to their initial antipsychotic treatment to receive either an increased antipsychotic dose or switch to a different antipsychotic drug. Nine hundred and two records were found and checked by the review authors.

Evidence found

Only one trial met the review requirements and provided usable data. Data were reported for the number of participants who responded to treatment, the general mental state of participants at endpoint of the trial and the presence of negative symptoms at endpoint. There were no data available for any other outcome. No clear difference between increasing the dose of the antipsychotic drug and switching to a different antipsychotic was shown. The available evidence was extremely limited and of very low quality.

Conclusions

The results of the present review show that there is no good-quality evidence to help clinicians decide between increasing the antipsychotic dose or switching to a different antipsychotic drug for people not responding to their initial antipsychotic treatment. Therefore, no clear conclusions can be drawn. Larger, well-designed trials are needed.

SUMMARY OF FINDINGS

Summary of findings for the main comparison. Increasing the antipsychotic dose compared to switching the antipsychotic drug for non response in schizophrenia

Increasing the antipsychotic dose compared to switching the antipsychotic drug for non responsein schizophrenia

Patient or population: patients with non response in schizophrenia

Settings: inpatients

Intervention: increasing the antipsychotic dose

Comparison: switching the antipsychotic drug

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Partici-	Quality of the evidence	Comments
	Assumed risk	Corresponding risk	(95% CI)	pants (studies)	(GRADE)	
	Switching the atipsychotic drug	Increasing the an- tipsychotic dose				
Global state: Clinically relevant re- sponse – as defined by trial Risk ratio Follow-up: mean 4 weeks	77 per 1000	125 per 1000 (13 to 1000)	RR 1.63 (0.17 to 15.99)	29 (1 study)	⊕000 very low ^{1,2}	
Leaving the study early: Tolerability –leaving the study early due to side ef- fects	See comment	See comment	Not estimable	0 (0)	See comment	No studies reported on this outcome.
Leaving the study early: Acceptabili- ty -leaving the study early due to any reason	See comment	See comment	Not estimable	0 (0)	See comment	No studies reported on this outcome,
General mental state –BPRS total score at endpoint* Weighted mean difference Follow-up: mean 4 weeks	The mean gener- al mental state – BPRS total score at endpoint in the control groups was 38.2 points in BPRS	The mean general mental state - BPRS to- tal score at endpoint in the intervention groups was 2 higher (4.2 lower to 8.2 high- er)		29 (1 study)	⊕000 very low ^{1,2}	Data for prespecified outcome: Clinical- ly important change were not reported.
Adverse effects –at least one adverse effect	See comment	See comment	Not estimable	0 (0)	See comment	No studies reported on this outcome.

Service use -time in hospital	See comment	See comment	Not estimable	0 (0)	See comment	No studies reported on this outcome.		
Quality of life –average change in quality of life	See comment	See comment	Not estimable	0 (0)	See comment	No studies reported on this outcome.		
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). CI: Confidence interval; RR: Risk ratio								

GRADE Working Group grades of evidence

High quality: further research is very unlikely to change our confidence in the estimate of effect.

Moderate quality: further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.

Low quality: further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.

Very low quality: we are very uncertain about the estimate.

¹ Imprecision: total (cumulative) sample size was just 29 participants and 95% confidence interval around the estimate of effect included no effect and appreciable benefit and appreciable harm; thus, very serious imprecision was present.

² Publication bias: strongly suspected as there is only one study.

4

Cochrane Library

Trusted evidence. Informed decisions. Better health.



BACKGROUND

A considerable number of people with schizophrenia do not respond to the first antipsychotic drug they are given at a dose their clinicians consider should be adequate (Barnes 2003; Lehmann 2004). Instead, they require multiple trials with different drugs before a satisfactory response is reached. Various strategies are used in such situations such as adding other antipsychotics, adding other psychotropic agents (e.g. mood stabilisers), increasing dose or switching to another antipsychotic. But which strategy is the best one is not clear. Switching antipsychotics is frequently applied in clinical practice, but there are many open questions. Is switching effective at all, for which drugs and after how much time? Guidelines originally recommended waiting for four to eight weeks before switching to another drug, arguing that the full efficacy of a given drug is reached after a longer period of treatment (Lehmann 2004; Falkai 2005). Recent data suggest, however, that nonresponders can be detected as early as two weeks after initiation of treatment (Agid 2003; Samara 2015). Another general possibility is to increase the dose of the currently prescribed antipsychotic. This approach is based on the premise that increasing the dose of an antipsychotic drug would lead to enhanced treatment efficacy (Kinon 2004). We aimed in this review to examine which strategy - increasing the antipsychotic dose or switching the antipsychotic drug — is the more promising in people who have not responded to an initial antipsychotic treatment.

Description of the condition

Schizophrenia is a chronic and disabling psychiatric disorder. It usually has an early onset and severe symptoms. It is one of the leading causes worldwide of long-term disability, with devastating impact for patients and their families. The degree of distress and disability is considerable; employment rates vary between 4.5% and 50% (Bouwmans 2015); and lifetime suicide prevalence is estimated around 5% (Palmer 2005). Quality of life for people suffering from schizophrenia is significantly low and it usually deteriorates during the course of the disease.

Antipsychotic medication is the current treatment of choice in schizophrenia (Kane 1996). Unfortunately, a large number of people experience no significant improvement despite pharmacological treatment (Lieberman 2005). These patients are often labelled as 'non-responders'. The exact epidemiology of this phenomenon is not clearly understood, one reason being that the criteria for non response or treatment resistance differ (Howes 2017). But guidelines say that approximately 20% to 30% of patients do not respond to an adequate trial of an antipsychotic drug (Lehmann 2004). There are no clear predictors of non response to antipsychotics, but it is well established that people with a first episode respond better than chronic patients (Jäger 2007).

Description of the intervention

Increasing the antipsychotic dose and switching the antipsychotic drug are two alternative strategies in the case of initial non response; it cannot be stated a priori which one is the intervention and which one the comparator. Thus, we briefly describe both.

Increasing the antipsychotic dose in non-responsive people with schizophrenia is often carried out in incremental steps: the dose is systematically increased until a clinical response is reached or the side effects become too severe and no further gain in

efficacy is obtained. In the 1970s and 1980s there was a notion that people with schizophrenia might benefit from mega doses of antipsychotics which might speed onset of action (sometimes called "rapid neuroleptisation"). Although this concept has been largely abandoned, because narrative reviews suggested that these excessive doses are not more efficacious in "general" patients (Baldessarini 1988), there is a possibility that some non-responders benefit from such doses. One reason could be that a considerable proportion of patients (up to 7% of Caucasians; Steijns 1998) have genetic polymorphism of liver enzymes of the CYP system which lead to a too-rapid metabolism of antipsychotics and non response. It could therefore be that at least some individual patients might well need higher doses beyond the officially approved ranges. A list of target doses and maximum doses recommended by international experts in schizophrenia is provided by Gardner 2010, for example. If higher doses than those approved by official labels are given, the major risk for people with schizophrenia is that they might experience more pronounced or severe side effects such as extrapyramidal symptoms, weight gain and prolonged QT interval.

Switching the antipsychotic drug can be broadly defined as changing a currently prescribed drug to a different one. For the current review, the reason for switching that we were interested in was due to insufficient therapeutic response to the original antipsychotic. Antipsychotics can be switched abruptly or gradually, and the timing of switching is also important; that is, how long an initial pharmacological treatment should have lasted. The major risk for people with schizophrenia can be that by switching from one antipsychotic to another, time is lost while patients would have benefited from staying on the same drug. Moreover at some stage during the switching process, patients are usually on two drugs which can lead to more side effects.

How the intervention might work

The idea behind increasing the antipsychotic dose is that for a nonresponsive person with schizophrenia, an individual threshold of sensitivity has to be reached for the drug to be effective. It is well known that considerable individual differences exist in respect to the pharmacokinetics of antipsychotics, which directly influence their efficacy (Miller 2009). A major factor are differences in the expression of cytochrome P450 enzymes which are responsible for the metabolism of many antipsychotic drugs. Polymorphisms in the genes coding these enzymes exist and can lead to their excessive expression and thus too-fast elimination of drugs (so called "ultrarapid metabolisers") and subsequent non response (Steijns 1998). More recent work suggested that some of the individual differences in response to antipsychotic drugs might have their source in the variability of ABCB1 genotypes, meaning that individuals with a favourable genotypic configuration show a lower risk of developing refractoriness to increasing antipsychotic dose (Vijayan 2012).

The idea behind switching the antipsychotic drug is based on the following: while all antipsychotics block dopamine receptors, they differ substantially in their effects on other receptors (Arnt 1998). Therefore, it could be that patients who do not respond to one antipsychotic drug might well respond to another one. Moreover, even when focusing only on the dopamine receptors there might be differences between individual patients. For example, a recent meta-analysis established that variations in the dopamine receptor D2 (DRD2) gene encoding the D₂ dopamine receptor are associated with clinical response to antipsychotic treatment (Zhang 2010).



Why it is important to do this review

It is estimated that between one-fifth and one-third of people with schizophrenia do not respond adequately to standard antipsychotic treatment (Barnes 2003). One of the major challenges in pharmacological treatment of the disorder is to help such patients to achieve complete remission of symptoms. Next to continuing a current treatment and hoping that patients will start responding with the passing of time, two competing strategies exist: increasing the dose of an antipsychotic; or switching to another one. Unfortunately, there is a lack of clear evidence to what extent these strategies are effective. Our aim is to provide a family of related systematic reviews of this topic in order to contribute to a more evidence-based clinical practice. The review is also potentially important for policy makers, because the high frequency of non response and treatment resistance leads to high rates of disability and thus costs for society (Vos 2012).

This review is part of three 'sibling' Cochrane Reviews, investigating non response in people with schizophrenia (the others being *Increasing antipsychotic dose for non response in schizophrenia* (Helfer 2015); and *Reducing antipsychotic dose for people with schizophrenia* (title only)).

OBJECTIVES

To examine the efficacy of increasing the antipsychotic dose versus switching the antipsychotic drug in the treatment of non-responsive people with schizophrenia.

METHODS

Criteria for considering studies for this review

Types of studies

All relevant randomised controlled trials. If a trial had been described as 'double-blind' but randomisation was implied, we would have included such trials in a sensitivity analysis (see Sensitivity analysis). We excluded quasi-randomised studies, such as those allocating by alternate days of the week. If people were given additional treatments within increasing dose or switching groups, we only included data if the adjunct treatment was evenly distributed between groups and it was only the increasing dose and switching groups that were randomised.

Types of participants

Adults, however defined, with schizophrenia or related disorders, including schizophreniform disorder, schizoaffective disorder and delusional disorder, by any means of diagnosis, who were non-responsive to their current antipsychotic treatment, irrespective of age, gender or race. We accepted any definition of non response that was used in the individual studies. It is a general strategy of the Cochrane Schizophrenia Group to also include studies which did not use operationalised diagnostic criteria such as those of the *Diagnostic and Statistical Manual of Mental Disorders* (DSM-5), because in clinical routine practice such criteria are not meticulously used either.

Types of interventions

1. Dose increase

Any increase of the antipsychotic dose, irrespectively of how it was defined. The new doses could be either within recommended

target dose ranges as described in the antipsychotics' labels or international recommendations, or higher (Gardner 2010).

2. Switching

Switching one antipsychotic to any other one, independently of the switching method or the time when the switch was made. There was no restriction in terms of the dose of the second antipsychotic, but if the dose of the new drug did not obviously match that of the original one (using Gardner 2010 as a standard), we recorded such details in our Assessment of risk of bias in included studies.

Types of outcome measures

We planned to divide, if possible, all outcomes into short term (up to 3 months), medium term (more than 3 months and up to 6 months) and long term (more than 6 months).

We reported binary outcomes, recording clear and clinically meaningful degrees of change (e.g. global impression of 'much improved', or more than 50% improvement on a rating scale, as defined within the trials) before any others. Thereafter we listed outcomes that are continuous.

Primary outcomes

1. Global state: clinically relevant response - as defined by trials*

* We expected that different trials would used different definitions of response. But studies have shown that, as long as relative measures of risk (relative risks, odds ratios) are applied, metaanalytic results do not differ much depending on the exact cut-off applied (Furukawa 2011).

2. Global state: exacerbations of psychosis - as defined by the authors

Secondary outcomes

1. Leaving the study early

- 1.1 Tolerability leaving early due to adverse effects
- 1.2 Acceptability leaving the study early due to any reason
- 1.3 Efficacy leaving early due to inefficacy of treatment

2. Mental state

2.1 General mental state

2.1.1 Clinically important change in general mental state – as defined by each of the studies

- 2.1.2 Average endpoint general mental state score
- 2.1.3 Average change in general mental state scores

2.2 Positive symptoms

2.2.1 Clinically important change in positive symptoms – as defined by each of the studies

Dy each of the studies

- 2.2.2 Average endpoint positive symptom score
- 2.2.3 Average change in positive symptom scores

2.3 Negative symptoms

2.3.1 Clinically important change in negative symptoms – as defined by each of the studies

2.3.2 Average endpoint negative symptom score

2.3.3 Average change in negative symptom scores



3. Depression

3.1 Clinically important change in depressive symptoms – as defined by each of the studies

3.2 Average endpoint depressive symptom score

3.3 Average change in depressive symptom scores

4. Aggressive behaviour

4.1 Clinically important change in aggressive behaviour – as defined by each of the studies

- 4.2 Average endpoint aggressive behaviour score
- 4.3 Average change in aggressive behaviour score

5. Exacerbations of psychosis (as defined by the individual studies)

5.1 Time ill (number of days in exacerbation)

6. Service use

6.1 Hospitalisation - time in hospital (days)

7. Adverse effects

7.1 At least one adverse effect

7.2 Specific side effects (as defined by the original authors, based on any reference values they applied)

8. Quality of life

8.1 Clinically important change in quality of life – as defined by each of the studies

8.2 Average endpoint quality of life

8.3 Average change in quality of life

9. Satisfaction with care

9.1 Clinically important change in satisfaction with care – as defined by each of the studies

9.2 Average endpoint satisfaction with care

9.3 Average change in satisfaction with care

'Summary of findings' table

We used the GRADE approach to interpret findings (Schünemann 2011); and the GRADE profiler to export data from this review and create the 'Summary of findings' tables (GRADE pro GDT). 'Summary of findings' tables provide outcome-specific information concerning the overall quality of evidence from each included study in the comparison, the magnitude of effect of the interventions examined, and the sum of available data on all outcomes that review authors rate as important to patient care and decision making.

We aimed to select the following main outcomes for inclusion in the 'Summary of findings' table.

- 1. Global state: clinically relevant response as defined by trial.
- 2. Leaving the study early: tolerability leaving early due to side effects.
- 3. Leaving the study early: acceptability leaving early due to any reason.
- 4. General mental state clinically important change in general mental state.
- 5. Adverse effects at least one adverse effect.
- 6. Service use time in hospital.
- 7. Quality of life clinically important change in quality of life.

If data were not available for these pre-specified outcomes but were available for ones that are similar, we presented the closest outcome to the pre-specified one in the table but took this into account when grading the finding.

Search methods for identification of studies

We did not apply any language restrictions, within the limitations of the search tools.

Electronic searches

1. Cochrane Schizophrenia Group's Study-Based Register of Trials

On 30 March 2017, the Information Specialist searched the register using the following search strategies:

(Dosage Increasing* AND Switch*) in Intervention Field of STUDY

This register is compiled by systematic searches of major resources (including AMED, BIOSIS, CINAHL, Embase, MEDLINE, PsycINFO, PubMed, and registries of clinical trials) and their monthly updates; handsearches; grey literature; and conference proceedings (see Group Module). There are no language, date, document type, or publication status limitations for inclusion of records in the register.

For previous searches, see Appendix 1.

Searching other resources

1. Reference searching

We inspected references of the included study for further relevant studies.

2. Personal contact

We contacted the first author of the included study for information regarding unpublished trials.

Data collection and analysis

Selection of studies

Two authors (MS and EK) independently inspected citations from the searches and identified relevant abstracts. Where disputes arose, we obtained the full-text reports for further assessment. We retrieved full reports of conference proceedings meeting the review criteria; the two authors (MS and EK) inspected these independently. We resolved disagreements by discussion with a third author (SL). If it had not been possible to resolve disagreement by discussion, we would have attempted to contact the authors of the study for clarification.

Data extraction and management

1. Extraction

Two authors (MS and EK) independently extracted data from the included study. We discussed any disagreement and, if necessary, consulted a third author (SL). We documented our decisions and, if necessary, we would have attempted to contact authors of the study for clarification. We would have extracted data presented only in graphs and figures whenever necessary and possible.

Increasing antipsychotic dose versus switching antipsychotic for non response in schizophrenia (Review) Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.



2. Management

2.1 Forms

We extracted data using pre-standardised data extraction forms.

2.2 Scale-derived data

We included continuous data from rating scales only if:

a) the psychometric properties of the measuring instrument have been described in a peer-reviewed journal (Marshall 2000);

b) the measuring instrument had not been written or modified by one of the trialists for that particular trial; and

c) the instrument is not a global assessment of an area of functioning and not sub-scores which are not, in themselves, validated or shown to be reliable. However there are exceptions: we would have included sub-scores from mental state scales measuring positive and negative symptoms of schizophrenia.

Ideally the measuring instrument should either be i. a self-report or ii. completed by an independent rater or relative (not the therapist). We realise that this is not often reported clearly; in 'Description of studies' we noted if this is the case or not.

2.3 Endpoint versus change data

There are advantages of both endpoint and change data. Change data can remove a component of between-person variability from the analysis. On the other hand calculation of change needs two assessments (baseline and endpoint) which can be difficult in unstable and difficult-to-measure conditions such as schizophrenia. We decided to primarily use endpoint data, and only use change data if the latter were not available. We combined endpoint and change data as we preferred to use mean differences (MD) rather than standardised mean differences (Deeks 2011).

2.4 Skewed data

Continuous data on clinical and social outcomes are often not normally distributed. To avoid the pitfall of applying parametric tests to non-parametric data, we aimed to apply the following standards to relevant continuous data before inclusion.

Standard deviations (SDs) and means that are reported in the paper or obtained from the authors.

For endpoint data from studies including fewer than 200 participants:

- when a scale starts from the finite number zero, we would have subtracted the lowest possible value from the mean, and divided this by the standard deviation. If this value is lower than one, it strongly suggests that the data are skewed and we would exclude these data. If this ratio is higher than one but less than two, there is a suggestion that the data are skewed: we would enter these data and test whether their inclusion or exclusion would change the results substantially. If such data changed results we would enter as 'other data'. Finally, if the ratio is larger than two we would included these data, because it is less likely that they are skewed (Altman 1996; Higgins 2011a).
- if a scale starts from a positive value (such as the Positive and Negative Syndrome Scale (PANSS), which can have values from 30 to 210 (Kay 1986)), we would modify the calculation described above to take the scale starting point into account. In these cases

Cochrane Database of Systematic Reviews

skewed data are present if 2 SD > (S – S min), where S is the mean score and 'S min' is the minimum score.

Please note: we would have entered all relevant data from studies of more than 200 participants in the analysis irrespective of the above rules, because skewed data pose less of a problem in large studies. We also would have entered all relevant change data, as when continuous data are presented on a scale that includes a possibility of negative values (such as change data), it is difficult to tell whether or not data are skewed.

2.5 Common measure

To facilitate comparison between trials, we intended to convert variables that could be reported in different metrics, such as days in hospital (mean days per year, per week or per month) to a common metric (e.g. mean days per month).

2.6 Conversion of continuous to binary

Where possible, we converted outcome measures to dichotomous data. This can be done by identifying cut-off points on rating scales and dividing participants accordingly into 'clinically improved' or 'not clinically improved'. It is generally assumed that if there is a 50% reduction in a scale-derived score such as the Brief Psychiatric Rating Scale (BPRS) or the Positive and Negative Syndrome Scale (PANSS) (Overall 1962; Kay 1986), this can be considered as a clinically significant response (Leucht 2005a; Leucht 2005b). If data based on these thresholds were not available, we used the primary cut-off presented by the original authors.

2.7 Direction of graphs

Where possible, we decided to enter data in such a way that the area to the left of the line of no effect would indicate a favourable outcome for the increased dose group. If this way made it impossible to avoid outcome titles with clumsy double-negatives (e.g. 'Not non-improved'), we decided to report data where the left of the line would indicate a favourable outcome for the switching group and noted this in the relevant graphs.

Assessment of risk of bias in included studies

Two authors (MS and EK) worked independently to assess risk of bias by using criteria described in the *Cochrane Handbook for Systematic Reviews of Interventions* (Higgins 2011b). This set of criteria is based on evidence of associations between overestimate of effect and high risk of bias of the article such as sequence generation, allocation concealment, blinding, incomplete outcome data and selective reporting.

If the authors disagreed, we would have made the final rating by consensus with involvement of a third author (SL). If inadequate details of randomisation and other characteristics of the trial were provided, we would have to contacted study authors in order to obtain further information. We would have reported nonconcurrence in quality assessment.

We noted the level of risk of bias in the text of the review (Risk of bias in included studies), the Characteristics of included studies table and Summary of findings for the main comparison.

Increasing antipsychotic dose versus switching antipsychotic for non response in schizophrenia (Review) Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.



Measures of treatment effect

1. Binary data

For binary outcomes we calculated standard estimations of risk ratios (RRs) and their 95% confidence intervals (CIs). It has been shown that RRs are more intuitive than odds ratios (ORs) (Boissel 1999), and that ORs tend to be interpreted as RRs by clinicians (Deeks 2000). The number needed to treat for an additional beneficial outcome (NNTB) and the number needed to treat for an additional harmful outcome (NNTH) with their CIs are intuitively attractive to clinicians but can be problematic both in terms of accurate calculation in meta-analyses and interpretation (Hutton 2009). For binary data presented in the 'Summary of findings' table, where possible we calculated illustrative comparative risks.

2. Continuous data

For continuous outcomes we estimated mean difference (MD) between groups. We preferred not to calculate effect size measures (standardised mean difference SMD). However, if scales of very considerable similarity were used, we presumed there was a small difference in measurement, and we calculated effect size and transformed the effect back to the units of one or more of the specific instruments.

Unit of analysis issues

1. Cluster trials

Studies increasingly employ 'cluster randomisation' (such as randomisation by clinician or practice) but analysis and pooling of clustered data poses problems. Firstly, authors often fail to account for intra-class correlation in clustered studies, leading to a 'unit of analysis' error (Divine 1992), whereby P values are spuriously low, CIs unduly narrow and statistical significance overestimated. This causes type I errors (Bland 1997; Gulliford 1999).

If clustering had not been accounted for in primary studies, we would have presented data in a table, with a (*) symbol to indicate the presence of a probable unit of analysis error. We would have attempted to contact first authors of studies to obtain intra-class correlation coefficients for their clustered data and to adjust for this by using accepted methods (Gulliford 1999). Where clustering is incorporated into the analysis of primary studies, we would have presented these data as if from a non-cluster randomised study, but adjusted for the clustering effect.

We have sought statistical advice and have been advised that binary data as presented in a report should be divided by a 'design effect'. This can be calculated using the mean number of participants per cluster (m) and the intraclass correlation coefficient (ICC) [Design effect = 1 + (m - 1) * ICC] (Donner 2002). If the ICC were not reported we would have assumed it to be 0.1 (Ukoumunne 1999).

If cluster studies had been appropriately analysed taking into account intra-class correlation coefficients and relevant data documented in the report, synthesis with other studies would be possible using the generic inverse variance technique.

2. Cross-over trials

A major concern of cross-over trials is the carry-over effect. It occurs if an effect (e.g. pharmacological, physiological or psychological) of the treatment in the first phase is carried over to the second phase. As a consequence on entry to the second phase the participants can differ systematically from their initial state despite a wash-out phase. For the same reason cross-over trials are not appropriate if the condition of interest is unstable (Elbourne 2002). As both effects are very likely in people with severe mental illness, we would have used only the data of the first phase of cross-over studies.

3. Studies with multiple treatment groups

Where a study involves more than two treatment arms, if relevant we would have presented the additional treatment arms in comparisons. If data were binary we would simply have added and combined within the two-by-two table. If data were continuous we would have combined data following the formula in the *Cochrane Handbook for Systematic Reviews of Interventions* (Higgins 2011a). Where the additional treatment arms were not relevant, we would not have used these data.

Dealing with missing data

1. Overall loss of credibility

We share the concern that at some degree of loss to follow-up, data must lose credibility (Xia 2010). However, it remains unclear which degree of attrition is problematic. Therefore, we did not exclude studies on the basis of degree of attrition, but considered attrition in our 'Risk of bias' assessment.

2. Binary

We decided to present data on a 'once randomised, always analyse' basis (an intention-to-treat (ITT) analysis). Those leaving the study early were all assumed to have the same rates of outcome as those who completed.

3. Continuous

3.1 Assumptions about participants who left the trials early or who were lost to follow-up

Various methods are available to account for participants who left the trials early or were lost to follow-up. Some trials just present the results of study completers, others use the method of 'last observation carried forward' (LOCF) (Leucht 2007), while more recently methods such as multiple imputation or mixedeffects models for repeated measurements have become more of a standard. While the second two methods seem to be somewhat better than LOCF (Leon 2006), we feel that the high percentage of participants leaving the studies early and differences in the reasons for leaving the studies early between groups is often the core problem in randomised schizophrenia trials. We therefore did not exclude studies based on the statistical approach used. However, we preferably used the more sophisticated approaches e.g. mixedeffects models for repeated measurements or multiple-imputation instead of LOCF, and we only presented completer analyses if some kind of ITT data were not available at all. Moreover, we addressed this issue in the item "incomplete outcome data" of the 'Risk of bias' tool.

3.2 Standard deviations

If standard deviations (SDs) were not reported, we tried to obtain the missing values from the authors. If SDs were not available, but an exact standard error (SE) and confidence intervals (CIs) were available for group means, and either the P value or t value were available for differences in the mean, we decided to calculate



them according to the rules described in the *Cochrane Handbook* for Systematic Reviews of Interventions (Higgins 2011a). When only the standard error (SE) was reported, SDs were calculated by the formula SD = SE * $\sqrt{(n)}$. The *Cochrane Handbook for Systematic Reviews of Interventions* presents detailed formulae for estimating SDs from P values, t or F values, CIs, ranges or other statistics (Higgins 2011a). If these formulae did not apply, we decided to calculate the SDs according to a validated imputation method which is based on the SDs of the other included studies (Furukawa 2006). Although some of these imputation strategies can introduce error, the alternative would be to exclude a given study's outcome and thus to lose information. We nevertheless decided to examine the validity of the imputations in a sensitivity analysis excluding imputed values.

Assessment of heterogeneity

1. Clinical heterogeneity

If we had included more than one study, we would have considered all included studies initially, without seeing comparison data, to judge clinical heterogeneity. We simply would have inspected all studies for clearly outlying people or situations which we had not predicted would arise. When such situations or participant groups arose, we would have discussed these.

2. Methodological heterogeneity

If we had included more than one study, we would have considered all included studies initially, without seeing comparison data, to judge methodological heterogeneity. We simply would have inspected all studies for clearly outlying methods which we had not predicted would arise. When such methodological outliers arose, we would have discussed these.

3. Statistical heterogeneity

3.1 Visual inspection

We would have visually inspected graphs to investigate the possibility of statistical heterogeneity.

3.2 Employing the I² statistic

We would have investigated statistical heterogeneity between studies by considering the I² statistic alongside the P value of the Chi² test. The I² statistic provides an estimate of the percentage of inconsistency thought to be due to chance (Higgins 2003). The importance of the observed value of the I² statistic depends on both the magnitude and direction of effects and the strength of evidence for heterogeneity (e.g. P value from the Chi² test, or CIs for the I² statistic). We would have considered an I² statistic estimate equal to or greater than 50%, accompanied by a statistically significant Chi² test (P value < 0.01) as evidence of substantial heterogeneity (Deeks 2011). If substantial levels of heterogeneity were found in the primary outcome, we would have explored reasons for heterogeneity (Subgroup analysis and investigation of heterogeneity).

Assessment of reporting biases

Reporting biases arise when the dissemination of research findings is influenced by the nature and direction of results (Egger 1997). These are described in Chapter 10 of the *Cochrane Handbook for Systematic Reviews of Interventions* (Sterne 2011).

1. Protocol versus full study

We tried to locate the protocol of the included trial. If the protocol is available, we compared outcomes in the protocol and in the published report . If the protocol is not available, we compared outcomes listed in the Methods section of the trial report with actually reported results.

We tried to locate the protocol of the included trial. If the protocol had been available, we would have compared outcomes in the protocol and in the published report. As the protocol was not available, we compared outcomes listed in the Methods section of the trial report with actually reported results.

2. Funnel plot

We are aware that funnel plots may be useful in investigating reporting biases but are of limited power to detect small-study effects. We did not plan to use funnel plots for outcomes where there are 10 or fewer studies, or where all studies are of similar size. If funnel plots are possible in future versions, we will seek statistical advice in their interpretation.

Data synthesis

We understand that there is no closed argument for preferring the use of a fixed-effect model over a random-effects models, or a random-effects model over a fixed-effect model. The randomeffects method incorporates an assumption that the different studies are estimating different, yet related, intervention effects. This does seem true to us as we (a priori) expected some clinical heterogeneity between participants in different trials. We therefore chose the random-effects model for all analyses (DerSimonian 1986). There is, however, a disadvantage to the random-effects model: it puts added weight onto small studies which often are the most biased ones. Depending on the direction of effect, these studies can either inflate or deflate the effect size.

Subgroup analysis and investigation of heterogeneity

1. Subgroup analyses

1.1 Antipsychotic drugs

We planned to perform subgroup analyses based on the antipsychotic drugs included in the selected studies.

1.2 Clinical state, stage or problem

We proposed to undertake this review and provide an overview of the effects of switching for people with schizophrenia in general. In addition, however, we aimed to report data on subgroups of people in the same clinical state, stage and with similar problems.

2. Investigation of heterogeneity

We planned to report relevant findings if heterogeneity was found to be high. Firstly, we would have investigated whether data had been entered correctly. Secondly, if data were correct, we would visually inspect the graph and particularly the studies outside of the company of the rest in order to identify reasons that might explain the heterogeneity. Decisions as to whether single studies are to be excluded from the analysis or whether a formal metaanalysis can be undertaken at all depend on issues such as whether the heterogeneity was due to differences in direction of effect or only to the degree of the differences between intervention and control (Higgins 2011a). If unanticipated clinical or methodological

Cochrane Library

Trusted evidence. Informed decisions. Better health.

heterogeneity had been obvious we would simply have stated hypotheses regarding these for future reviews or versions of this review. We did not anticipate undertaking analyses relating to these.

Sensitivity analysis

1. Implication of randomisation

We aimed to include trials in a sensitivity analysis if they were described in some way as to imply randomisation. For the primary outcomes we planned to include these studies and if their inclusion did not result in a substantive difference, they would have remained in the analyses. If their inclusion resulted in important clinically significant differences — but not necessarily statistically significant differences — we planned not to add the data from these lower-quality studies to the results of the better trials, but would have presented such data within a subcategory.

2. Risk of bias

We aimed to analyse the effects of excluding trials that were judged to be at high risk of bias across one or more of the domains; see Assessment of risk of bias in included studies. If the exclusion of trials at high risk of bias did not substantially alter the direction of effect or the precision of the effect estimates, we would have included data from these trials in the analysis. Studies with a high risk of bias in terms of randomisation or allocation concealment would have been excluded right from the start. If randomisation and allocation methods were described (and risk of bias was rated as unclear) we planned to enter such trials in a sensitivity analysis.

3. Imputed values

If assumptions had to be made regarding missing SDs (see Dealing with missing data), we planned to compare the findings of the primary outcomes when we used our assumption/s and when we used data only from studies which provided SDs.

We also planned to undertake a sensitivity analysis to assess the effects of including data from trials where imputed values for ICC in calculating the design effect in cluster randomised trials were used.

4. Fixed effect and random effects

We synthesised data using a random-effects model; however, if possible, we would have synthesised data for the primary outcomes using a fixed-effect model to evaluate whether this would alter the results.

If substantial differences had been noted in the direction or precision of effect estimates in any of the sensitivity analyses listed above, we would not have pooled data from the excluded trials with the other trials contributing to the outcome, but would have presented them separately.

RESULTS

Description of studies


For substantive description of studies please see Characteristics of included studies and Characteristics of excluded studies.

Results of the search

The initial search of the Cochrane Schizophrenia Group Trials Register in June 2014 yielded 543 records. We additionally made two later searches of the same Trials Register (using the same search strategy), one in October 2015 which yielded 358 records and one in March 2017 which yielded one record. After we removed duplicates, we screened 819 records and excluded 781 at abstract and title stage. We obtained and closely inspected 38 full-text reports on 26 studies; and as a result we included one study (referring to two full-text reports) and excluded 25 studies (referring to 36 full-text reports) (see Figure 1).



Figure 1. Study flow diagram for trial selection up to March 2017



Increasing antipsychotic dose versus switching antipsychotic for non response in schizophrenia (Review) Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.



Only one study met inclusion criteria for this review (Kinon 1993). The study was published in 1993 (for more details, see Characteristics of included studies and the accompanying 'Risk of bias' table).

1. Study design

Kinon 1993 had two phases. The first phase was an open-label, non-comparative design. The second phase was a double-blind, randomised, interventional design.

2. Length of trial

Kinon 1993 had a total duration of eight weeks; each phase had a duration of four weeks. In the first phase, all participants received fluphenazine 20 mg/day plus benztropine 4 mg/day openly for four weeks. Non-responders of the first phase then entered the second, double-blind phase of another four weeks' duration.

3. Participants

One hundred and fifty-six participants entered the study. Out of 115 participants that completed the first four weeks of treatment, 37 were responders and 78 were non-responders. Fifty-eight of the 78 non-responder participants entered the double-blind phase of the study, but data were presented only for 47 of them (see also Characteristics of included studies).

All 156 participants initially entering the Kinon 1993 study were inpatients and had a diagnosis of schizophrenia (76.9%), schizoaffective disorder (16.7%) or schizophreniform disorder (6.4%) according to DSM-III-R criteria (American Psychiatric Association 1987). One hundred participants were men; 56 were women. The mean age of participants was 29.4 ± 7.0 years, the age at first hospitalisation was 23.0 ± 6.5 years and the number of previous hospitalisations was 2.6 ± 2.2 .

4. Interventions

In the second phase of the Kinon 1993 study, 58 participants (of the 78 non-responders to fluphenazine 20 mg/day during the first phase of the study) were randomly assigned to doubleblind treatment with either fluphenazine 20 mg/day, fluphenazine 80 mg/day or haloperidol 20 mg/day, all supplemented with benztropine. Data were available for 47 out of 58 participants entering the double-blind phase of the study: fluphenazine 20 mg/ day (N = 18), fluphenazine 80 mg/day (N = 16) and haloperidol 20 mg/day (N = 13). For the purpose of the present review, 29 participants were of interest (fluphenazine 80 mg/day (N = 16) and haloperidol 20 mg/day (N = 13)).

5. Outcomes

5.1 Outcome scales

A variety of scales were used to assess clinical response and adverse events. Details of scales that provided usable data are shown below.

5.1.1 Global state

Clinical Global Impression - CGI (Guy 1976)

CGI is a 7-point rating instrument that is commonly used in studies on schizophrenia. It enables clinicians to quantify severity of illness (CGI-Severity) or overall clinical improvement (CGI-Improvement) during therapy with low scores indicating decreased severity or greater improvement.

5.1.2 Mental state

Brief Psychiatric Rating Scale – BPRS (Overall 1962)

The BPRS is a scale used to measure the severity of psychiatric symptoms, including psychotic symptoms. The scale has usually 18 items (depending on the version the number of items could vary from 16 to 24), and each item is rated on a 7-point scoring system varying from 'not present' (1) to 'extremely severe' (7). Higher scores indicate more pronounced symptomatology.

Scale for the Assessment of Negative Symptoms – SANS (Andreasen 1982)

The SANS is a scale used to measure the severity of negative symptoms in schizophrenia. The scale is used to evaluate five domains of symptoms: alogia; affective blunting; avolition-apathy; anhedonia-asociality; and attention impairment. Each symptom is rated on a 6-point scoring system varying from 'absent' (0) to 'severe' (5). Higher scores indicate more pronounced symptomatology.

5.1.3 Adverse events

Simpson Angus Scale – SAS (Simpson 1970)

This 10-item scale, with a scoring system of 0 to 4 for each item, measures drug-induced parkinsonism, a short-term drug-induced movement disorder. A low score indicates low levels of parkinsonism.

Excluded studies


We excluded 36 full-text articles on 26 trials. We excluded three studies because they were not appropriately randomised (Suzuki 2007; Agid 2013; Kim 2013). We excluded the remaining studies because of wrong interventions, e.g. no antipsychotic dose increase group or no antipsychotic switching group.

Risk of bias in included studies

For graphical representations of our judgements of risk of bias please refer to Figure 2 and Figure 3. Full details of judgements are seen in the 'Risk of bias' table.



Figure 2. Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.





	Random sequence generation (selection bias)	Allocation concealment (selection bias)	Blinding of participants and personnel (performance bia	Blinding of outcome assessment (detection bias)	Incomplete outcome data (attrition bias)	Selective reporting (reporting bias)	Other bias	
Kinon 1993	?	?	?	?	?	Θ	÷	

Figure 3. Risk of bias summary: review authors' judgements about each risk of bias item for each inclu	ded study.
--	------------

ິທ ຕ

Allocation

Concerning random sequence generation and allocation concealment, we rated Kinon 1993 with an unclear risk of bias for

both; it was described as "randomised", but no detail on allocation concealment was provided.



Blinding

Concerning performance bias and detection bias, we rated Kinon 1993 with an unclear risk of bias; it was described as "double-blind", but no detail was provided regarding blinding of participants, personnel or assessors.

Incomplete outcome data

Concerning attrition bias, we rated Kinon 1993 with an unclear risk of bias since the issue of numbers leaving the study early was not addressed. Furthermore, data were presented for just 81% (47/58) of all randomised participants.

Selective reporting

Concerning reporting bias, we rated Kinon 1993 with a high risk of bias since SAS scores were available only for two items and not total.

Other potential sources of bias

We judged Kinon 1993 to be free of other potential sources of bias.

Effects of interventions

See: Summary of findings for the main comparison Increasing the antipsychotic dose compared to switching the antipsychotic drug for non response in schizophrenia

We did not perform any meta-analysis as only one study was included in the review. In the first phase of Kinon 1993, all participants received fluphenazine 20 mg/day plus benztropine 4 mg/day openly for 4 weeks. In the second phase, 58 non-responders to fluphenazine 20 mg/day of the first phase were randomly assigned to double-blind treatment with either fluphenazine 20 mg/day, fluphenazine 80 mg/day or haloperidol 20 mg/day, all supplemented with benztropine 4 mg/day. Data were reported only for 47 out of 58 initially randomised participants.

See: Summary of findings for the main comparison of the available outcomes for the comparison 'Increasing the antipsychotic dose versus switching the antipsychotic drug'.

1. Increasing the antipsychotic dose versus switching the antipsychotic drug

1.1 Global state

1.1.1 Clinically relevant response – as defined by the authors

Kinon 1993 provided data on the number of responders. Response was defined by a combination of criteria: a rating of 'mild' or better on each of the four BPRS psychotic items and a rating of 'much improved' or better in CGI-Improvement scale. Two out of 16 participants in the dose increase group, one out of 13 participants in the switching the antipsychotic drug group and one out of 18 participants in the continuing with the same dose and drug group were judged to be responders. There was no clear difference between the antipsychotic dose increase group versus the antipsychotic switching group in this regard (RR 1.63, CI 0.17 to 15.99, 1 RCT, N = 29, very low quality evidence, Analysis 1.1).

1.2 Mental state

1.2.1 General mental state – average endpoint score (BPRS total, high = poor)

Kinon 1993 reported the average BPRS total score at endpoint per group (dose increase: 40.2 points \pm 10.4 versus switching: 38.2 points \pm 6.5). There was no clear difference between antipsychotic dose increase versus antipsychotic switching group in this regard (MD 2.00, Cl –4.20 to 8.20, 1 RCT, N = 29, *very low quality evidence*, Analysis 1.2).

1.2.2 Negative symptoms - average endpoint score (SANS, high = poor)

Kinon 1993 reported the average SANS total score at endpoint per group (dose increase: 55.5 ± 26 versus switching: 52.1 ± 17.67). There was no clear difference between antipsychotic dose increase versus antipsychotic switching group in this regard (MD 3.40, Cl -12.56 to 19.36, 1 RCT, N = 29, Analysis 1.3).

2. Subgroup analysis and investigation of heterogeneity

Only one study was included in our review. Therefore, no subgroup analysis could be performed.

3. Publication bias

Only one study was included in our review. Therefore, a funnel plot analysis could not be performed.

4. Sensitivity analyses

Only one study was included in our review. Therefore, no sensitivity analysis could be performed.

DISCUSSION

Summary of main results

Despite our comprehensive search we included just one small study — Kinon 1993 — in the present review. Kinon 1993 compared increasing the antipsychotic dose versus switching the antipsychotic drug versus continuation with the same antipsychotic dose and drug in people with schizophrenia or related disorders who were non-responsive to their initial antipsychotic treatment. The included study was published in 1993. The initial phase was open treatment with fluphenazine 20 mg/day for four weeks. Non-responders were then randomised to increasing the fluphenazine dose to 80 mg/day, switching to haloperidol 20 mg/day or continuing treatment with fluphenazine at the same, initial dose of 20 mg/day for four additional weeks. No difference in any efficacy outcome (clinical response, BPRS at endpoint, SANS at endpoint) was shown among the three alternative treatment options.

Overall completeness and applicability of evidence

Only one study examined whether dose increase is more efficacious than switching the antipsychotic drug in people with schizophrenia not responding to their current antipsychotic treatment. We excluded studies that did not exclusively examine non-responders, but included participants with treatment intolerance as well, from the present review. Conclusions based on the data of the present systematic review are extremely limited by the inclusion of only one RCT with a small number of participants and only three reported outcomes. All in all, at present there is insufficient evidence to draw any firm conclusions and more studies are needed.



Kinon 1993 was described as randomised and double-blind, but no detail was provided. Therefore it is unclear whether the study was adequately randomised, whether treatment allocation was really concealed and whether blinding worked. Moreover, the study did not address missing outcome data, either in numbers leaving early or regarding reasons, and did not report on other pre-specified outcomes of importance such as adverse effects, service use and quality of life. But even for the three outcomes (clinical response, overall mental state and negative symptoms) that were adequately reported, the sample size was not large enough (N = 29) to detect any clear difference even if a difference existed (i.e. type II error). Overall the quality of the evidence of Kinon 1993 was very low for all outcomes based on GRADE (Schünemann 2011).

Potential biases in the review process

We attempted to limit bias in every step of the review process. We pre-specified and published the study protocol, our search was comprehensive, our selection criteria were clear and strict, we extracted all outcomes and at least two authors selected the studies and extracted the data. But we mainly based the search on the Cochrane Schizophrenia's register of trials which is largely made up of searches of published literature. Therefore, it is possible that there are unpublished studies that we are not aware of and there is a possibility of publication bias. Moreover, we were unable to undertake the proposed funnel plot to investigate the presence of publication bias since only one study was included in this review.

Agreements and disagreements with other studies or reviews

An expert consensus recommended increasing the antipsychotic dose, especially for second generation and depot antipsychotics, before considering switching the antipsychotic drug to a different agent (Kane 2003). Nevertheless, schizophrenia treatment guidelines acknowledge that limited evidence exists in favour of increasing the antipsychotic dose outside the recommended dose ranges for patients with schizophrenia who do not respond to their initial antipsychotic treatment (Lehmann 2004; Buchanan 2010; Hasan 2012). On the other hand, it is recognized that some studies indicate that a switch from first-generation antipsychotics (FGAs) or second-generation antipsychotics (SGAs) to certain SGAs might be promising (Hasan 2012). Previous reviews examining the alternative treatment strategies in case of non response to initial antipsychotic treatment - Leucht 2013, Leucht 2015 and Dold 2014 — also only found the Kinon 1993 study for the specific comparison of increasing the dose versus switching the drug, but differences in the inclusion and exclusion criteria were present and no quantitative synthesis (meta-analysis) was planned to be conducted.

AUTHORS' CONCLUSIONS

Implications for practice

1. For people with schizophrenia

For people with schizophrenia, it is critical to know which treatment strategy should be followed in case of non response to initial antipsychotic treatment. Any clinical decision should take into account the medical history of the patient.

2. For clinicians

There is currently extremely limited evidence to draw any safe conclusion for the comparison between increasing the antipsychotic dose versus switching the antipsychotic drug in case of people with schizophrenia who do not respond to their initial antipsychotic treatment. The only available data for this review came from just one small RCT (N = 29) and we can provide no clear conclusion regarding one treatment option over the other.

3. For managers/policy makers

We found no data for economic outcomes.

Implications for research

1. General

Outcome reporting remains insufficient in antipsychotic drug trials. Strict adherence to the CONSORT statement (**CON**solidated **S**tandards **O**f **R**eporting **T**rials; Moher 2001; Moher 2012) would make such studies much more informative.

2. Specific

Further studies are urgently warranted to investigate the optimal treatment strategy when a patient does not respond to the initial antipsychotic treatment. For a suggested study design please see Table 1.

ACKNOWLEDGEMENTS

The Cochrane Schizophrenia Group Editorial Base in Nottingham produces and maintains standard text for use in the Methods section of their reviews. We have used this text as the basis of what appears here and adapted it as required.

The search term was developed by the Trial Search Co-ordinator of the Cochrane Schizophrenia Group and the contact author of this review.

We would like to thank Dr Georgios Mikellides for peer reviewing the protocol and Joey Kwong for copy editing. We also thank Wing Chung Chang, Yuen-Shan Ho and Brittany Dutton for peer reviewing the full review version.



REFERENCES

References to studies included in this review

Kinon 1993 {published data only}

Johns CA, Mayerhoff DI, Lieberman JA, Kane JM. Schizophrenia: alternative neuroleptic strategies. In: Angrist B/Schulz SC editor(s). The Neuroleptic-Nonresponsive Patient: Characterization and Treatment. Washington, DC, USA: American Psychiatric Press, Inc, 1990:53-66.

Kane JM, Kinon B, Johns C. Alternative strategies for treating neuroleptic nonresponsive patients. *Schizophrenia Research* 1993;**9**:240.

* Kinon BJ, Kane JM, Johns C, Perovich R, Ismi M, Koreen A, et al. Treatment of neuroleptic-resistant schizophrenic relapse. *Psychopharmacology Bulletin* 1993;**29**(2):309-14.

References to studies excluded from this review

Agid 2013 {published data only}

Agid O, Schulze L, Arenovich T, Sajeev G, McDonald K, Foussias G, et al. Antipsychotic response in first-episode schizophrenia: efficacy of high doses and switching. *European Neuropsychopharmacology* 2013;**23**(9):1017-22.

Bondolfi 1995 {published data only}

Bondolfi G, Baumann P, Patris M, May J, Billeter U, Dufour H, et al. A randomized double-bind trial of risperidone versus clozapine for treatment-resistant chronic schizophrenia. *European Neuropsychopharmacology* 1995;**5**(3):349.

Buckley 1995 {published data only}

Buckley PF, Cola PA, Hasegawa M, Lys C, Meltzer HY. Plasma levels and dosing strategies in schizophrenic patients receiving clozapine. *Schizophrenia Research* 1995;**15**(1-2):144.

Conley 2003 {published data only}

Conley RR, Kelly DL, Richardson CM, Tamminga CA, Carpenter W. The efficacy of high-dose olanzapine versus clozapine in treatment-resistant schizophrenia: a doubleblind, crossover study. *Journal of Clinical Psychopharmacology* 2003;**23**(6):668-71.

Dunn 2005 {published data only}

* Dunn J, Kane J, Khanna S, Giller E, Rajadhyaksha S, Loebel A. Ziprasidone in treatment - resistant schizophrenia: long - term efficacy and tolerability. *Schizophrenia Bulletin* 2005;**31**:481-2.

Khanna S, Rajadhyaksha S, Kane J, Giller E. Ziprasidone versus chlorpromazine in treatment-refractory schizophrenia. *Schizophrenia Research* 2003;**60**(1):289-90.

Ganguli 2003 {published data only}

Ganguli R, Berry S, Gharabawi G, Lonchena C, Mahmoud R, Brar J, et al. Randomized assessment of strategies for switching patients with sub-optimal treatment outcomes from olanzapine to risperidone. *Schizophrenia Research* 2003;**60**(1):283.

Goff 2013 {published data only}

* Goff DC, McEvoy JP, Citrome L, Mech AW, Bustillo JR, Gil R, et al. High-dose oral ziprasidone versus conventional dosing in schizophrenia patients with residual symptoms: The ZEBRAS study. *Journal of Clinical Psychopharmacology* 2013;**33**(4):485-90.

NCT00403546. High-dose oral ziprasidone versus conventional dosing in schizophrenia patients with residual symptoms. clinicaltrials.gov/show/NCT00403546 (accessed 22 January 2016).

Harvey 2007 {published data only}

Harvey P, Warrington L, Loebel A, Romeo F, Gorini B, Galluzzo A, et al. Cognitive effects of ziprasidone and clozapine: results from an 18-week double-blind trial. *European Neuropsychopharmacology* 2007;**17**(Suppl 4):S439.

Hatta 2012 {published data only}

Hatta K, Otachi T, Sudo Y, Kuga H, Takebayashi H, Hayashi H, et al. A comparison between augmentation with olanzapine and increased risperidone dose in acute schizophrenia patients showing early non-response to risperidone. *Psychiatry Research* 2012;**198**(2):194-201.

Honer 2010 {published data only}

Honer WG, MacEwan GW, Gendron A, Stip E, Labelle A, Williams R, et al. A double blind, placebo controlled study of the safety and tolerability of quetiapine 1200 mg/d versus 800 mg/d in patients with persistent symptoms of schizophrenia or schizoaffective disorder. *Schizophrenia Research* 2010;**117**(2-3):375.

* Honer WG, MacEwan GW, Gendron A, Stip E, Labelle A, Williams R, et al. A randomized, double-blind, placebocontrolled study of the safety and tolerability of highdose quetiapine in patients with persistent symptoms of schizophrenia or schizoaffective disorder. *Journal of Clinical Psychiatry* 2012;**73**(1):13-20.

Janicak 1994 {published data only}

Janicak PG, Javaid JI, Sharma RP, Leach A, Dowd S, Blake L, et al. Random assignment to 3 haloperidol plasma-levels for acute-psychosis. *Biological Psychiatry* 1994;**35**(9):666.

Kane 1988 {published data only}

Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. *Archives of General Psychiatry* 1988;**45**(9):789-96.

Kane 2007 {published data only}

Kane JM, Meltzer HY, Carson W, McQuade RD, Marcus RN, Sanchez R. Aripiprazole for treatment-resistant schizophrenia: results of a multicenter, randomized, double-blind, comparison study versus perphenazine. *Journal of Clinical Psychiatry* 2007;**68**(2):213-23.



Kim 2013 {published data only}

Kim EY, Chang SM, Shim JC, Joo EJ, Kim JJ, Kim YS, et al. Longterm effectiveness of flexibly dosed paliperidone extendedrelease: comparison among patients with schizophrenia switching from risperidone and other antipsychotic agents. *Current Medical Research and Opinion* 2013;**29**(10):1231-40.

Kinon 2010 {published data only}

Kinon B, Chen L, Stauffer V, Ascher-Svanum H, Zhou W, Kollack-Walker S, et al. Differences between early responders and early non-responders to atypical antipsychotics on symptom and functional outcomes in the treatment of schizophrenia. *Schizophrenia Research* 2010;**117**(2-3):132.

Kinon BJ, Chen L, Ascher-Svanum H, Stauffer V, Kollack-Walker S, Zhou W, et al. Early response as a response predictor: Use of individual variability in clinical trials. *European Neuropsychopharmacology* 2009;**19**(Suppl 3):S183.

Kinon BJ, Chen L, Ascher-Svanum H, Stauffer VL, Kollack-Walker S, Zhou W, et al. Challenging the assumption that improvement in functional outcomes is delayed relative to improvement in symptoms in the treatment of schizophrenia. *Schizophrenia Research* 2010;**118**(1-3):176-82.

* Kinon BJ, Chen L, Ascher-Svanum H, Stauffer VL, Kollack-Walker S, Zhou W, et al. Early response to antipsychotic drug therapy as a clinical marker of subsequent response in the treatment of schizophrenia. *Neuropsychopharmacology* 2010;**35**(2):581-90.

Kinon BJ, Stauffer V, Ascher-Svanum H, Tomori O, Kollack-Walker S. Predicting response to risperidone treatment through identification of early-onset of antipsychotic drug action in schizophrenia. Proceedings of the 161st Annual Meeting of the American Psychiatric Association. Washington DC, May 3-8, 2008.

Stauffer V, Chen L, Ascher-Svanum H, Kollack-Walker S, Zhou W, Kapur S, et al. Switching antipsychotic drugs enhances improvement in patients who show lack of an early response to their initial antipsychotic therapy. Proceedings of the 162nd Annual Meeting of the American Psychiatric Association. San Francisco, CA, 2009 May 16-21.

Lindenmayer 2011 {published data only}

Lindenmayer JP, Citrome L, Khan A, Kaushik S. A randomized, double-blind, parallel-group, fixed-dose, clinical trial of quetiapine at 600 versus 1200 mg/d for patients with treatmentresistant schizophrenia or schizoaffective disorder. *Journal of Clinical Psychopharmacology* 2011;**31**(2):160-8.

McEvoy 2013 {published data only}

McEvoy J, Citrome L, Hsu J, Werner P, Pikalov A, Cucchiaro J, et al. Switching to lurasidone in patients with schizophrenia: Tolerability and effectiveness at 6 weeks and 6 months. *European Psychiatry* 2013;**28**(Suppl. 1):Article: 1046.

* McEvoy JP, Citrome L, Hernandez D, Cucchiaro J, Hsu J, Pikalov A, et al. Effectiveness of lurasidone in patients with schizophrenia or schizoaffective disorder switched from other antipsychotics: A randomized, 6-week, open-label study. *Journal of Clinical Psychiatry* 2013;**74**(2):170-9. McEvoy JP, Citrome L, Hernandez D, Hsu J, Werner P, Pikalov A, et al. Switching to lurasidone in patients with schizophrenia: tolerability and effectiveness at 6 weeks and 6 months. *European Neuropsychopharmacology* 2013;**23**(2):S486.

McEvoy JP, Citrome L, Hsu J, Werner P, Pikalov A, Cucchiaro J, et al. Switching to lurasidone in patients with schizophrenia: Tolerability and effectiveness at 6 weeks and 6 months. *Schizophrenia Bulletin* 2013;**39**:S343.

NCT00161018 {published data only}

NCT00161018. New antipsychotic strategies: quetiapine and risperidone vs. fluphenazine in treatment resistant schizophrenia. clinicaltrials.gov/show/NCT00161018 (accessed 22 January 2016).

NCT00191555 {published data only}

NCT00191555. Efficacy study of switching stabilized schizophrenic patients from conventional to atypical antipsychotic treatment. clinicaltrials.gov/ct2/show/ NCT00191555 (accessed 22 January 2016).

Potkin 1994 {published data only}

Potkin SG, Bera R, Gulasekaram B, Costa J, Hayes S, Jin Y, et al. Plasma clozapine concentrations predict clinical response in treatment-resistant schizophrenia. *Journal of Clinical Psychiatry* 1994;**55**(Suppl B):133-6.

Sacchetti 2009 {published data only}

Sacchetti E, Galluzzo A, Valsecchi P, Romeo F, Gorini B, Warrington L. Ziprasidone vs clozapine in schizophrenia patients refractory to multiple antipsychotic treatments: the MOZART study. *Schizophrenia Research* 2009;**110**(1-3):80-9.

Simpson 1999 {published data only}

Simpson GM, Josiassen RC, Stanilla JK, de Leon J, Nair C, Abraham G, et al. Double blind study of clozapine dose response in chronic schizophrenia. *American Journal of Psychiatry* 1999;**156**(11):1744-50.

Suzuki 2007 {published data only}

Suzuki T, Uchida H, Watanabe K, Nomura K, Takeuchi H, Tomita M, et al. How effective is it to sequentially switch among olanzapine, quetiapine and risperidone? - A randomized, openlabel study of algorithm-based antipsychotic treatment to patients with symptomatic schizophrenia in the real-world clinical setting. *Psychopharmacology* [*psychopharmacologia*] 2007;**195**(2):285-95.

Weiden 2003 {published data only}

Weiden PJ, Simpson GM, Potkin SG, O'Sullivan RL. Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia. *Journal of Clinical Psychiatry* 2003;**64**(5):580-8.

Wirshing 1999 {published data only}

Wirshing DA, Marshall B, Green MF, Mintz J, Marder SR, Wirshing WC. Risperidone in treatment-refractory schizophrenia. *American Journal of Psychiatry* 1999;**156**(9):1374-9.



Additional references

Agid 2003

Agid O, Kapur S, Arenovich T, Zipursky RB. Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected. *Archives of General Psychiatry* 2003;**60**(12):1228-35.

Altman 1996

Altman DG, Bland JM. Detecting skewness from summary information. *BMJ* 1996;**313**(7066):1200.

American Psychiatric Association 1987

American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 3rd Edition. Washington, DC: APA, 1987.

Andreasen 1982

Andreasen NC, Olsen S. Negative vs. positive schizophrenia: Definition and validation. *Archives of General Psychiatry* 1982;**39**(7):789-94.

Arnt 1998

Arnt J, Skarsfeldt T. Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. *Neuropsychopharmacology* 1998;**18**(2):63-101.

Baldessarini 1988

Baldessarini RJ, Cohen BM, Teicher MH. Significance of neuroleptic dose and plasma level in the treatment of psychoses. *Archives of General Psychiatry* 1988;**45**(1):79-91.

Barnes 2003

Barnes TR, Buckley P, Schulz, SC. Treatment-resistant schizophrenia. In: Hirsch SR, Weinberger D editor(s). Schizophrenia. 2nd Edition. Oxford: Blackwell Science Ltd, 2003:489–516.

Bland 1997

Bland JM. Statistics notes. Trials randomised in clusters. *BMJ* 1997;**315**(7108):600.

Boissel 1999

Boissel JP, Cucherat M, Li W, Chatellier G, Gueyffier F, Buyse M, et al. The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use [Apercu sur la problematique des indices d'efficacite therapeutique, 3: comparaison des indices et utilisation. Groupe d'Etude des Indices D'efficacite]. *Therapie* 1999;**54**(4):405-11. [PUBMED: 10667106]

Bouwmans 2015

Bouwmans C, de Sonneville C, Mulder CL, Hakkaart-van Roijen L. Employment and the associated impact on quality of life in people diagnosed with schizophrenia. *Neuropsychiatric Disease and Treatment* 2015;**11**:2125-42.

Buchanan 2010

Buchanan RW, Kreyenbuhl J, Kelly DL, Noel JM, Boggs DL, Fischer BA, et al. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. *Schizophrenia Bulletin* 2010;**36**(1):71-93.

Deeks 2000

Deeks J. Issues in the selection for meta-analyses of binary data. Proceedings of the 8th International Cochrane Colloquium. Cape Town: The Cochrane Collaboration, 25-28 Oct 2000.

Deeks 2011

Deeks JJ, Higgins JP, Altman DG. Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.

DerSimonian 1986

DerSimonian R, Laird N. Meta-analysis in clinical trials. *Controlled Clinical Trials* 1986;**7**(3):177-88.

Divine 1992

Divine GW, Brown JT, Frazier LM. The unit of analysis error in studies about physicians' patient care behavior. *Journal of General Internal Medicine* 1992;**7**(6):623-9.

Dold 2014

Dold M, Leucht S. Pharmacotherapy of treatment-resistant schizophrenia: a clinical perspective. *Evidence-based Mental Health* 2014;**17**(2):33-7.

Donner 2002

Donner A, Klar N. Issues in the meta-analysis of cluster randomized trials. *Statistics in Medicine* 2002;**21**(19):2971-80.

Egger 1997

Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. *BMJ* 1997;**315**(7109):629-34.

Elbourne 2002

Elbourne D, Altman DG, Higgins JP, Curtina F, Worthingtond HV, Vaile A. Meta-analyses involving cross-over trials: methodological issues. *International Journal of Epidemiology* 2002;**31**(1):140-9.

Falkai 2005

Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, Möller HJ, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment ofschizophrenia, Part 1: acute treatment of schizophrenia. *World Journal of Biological Psychiatry* 2005;**6**(3):132-92.

Furukawa 2006

Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N. Imputing missing standard deviations in meta-analyses can provide accurate results. *Journal of Clinical Epidemiology* 2006;**59**(7):7-10.

Furukawa 2011

Furukawa TA, Akechi T, Wagenpfeil S, Leucht S. Relative indices of treatment effect may be constant across different definitions of response in schizophrenia trials. *Schizophrenia Research* 2011;**126**(1-3):212-9.



Gardner 2010

Gardner DM, Murphy AL, O'Donnell H, Centorrino F, Baldessarini RJ. International consensus study of antipsychotic dosing. *American Journal of Psychiatry* 2010;**167**(6):686-93.

Gulliford 1999

Gulliford MC. Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994. *American Journal of Epidemiology* 1999;**149**(9):876-83.

Guy 1976

Guy W. ECDEU assessment manual for psychopharmacology-Revised. ECDEU assessment manual for psychopharmacology-Revised. Rockville, Maryland, USA: National Institute of Mental Health, 1976.

Hasan 2012

Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, et al. World federation of societies of biological psychiatry (WFSBP) guidelines for the biological treatment of schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. *World Journal of Biological Psychiatry* 2012;**13**(5):318-78.

Helfer 2015

Helfer B, Leucht SL, Rothe PH, Samara MT. Increasing antipsychotic dose for non response in schizophrenia. *Cochrane Database of Systematic Reviews* 2015, Issue 10. [DOI: 10.1002/14651858.CD011883]

Higgins 2003

Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *BMJ* 2003;**327**(7414):557-60.

Higgins 2011a

Higgins JP, Green S. Chapter 7: Selecting studies and collecting data. In: Higgins JP, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.

Higgins 2011b

Higgins JP, Altman DG, Sterne JA. Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.

Howes 2017

Howes OD, McCutcheon R, Agid O, de Bartolomeis A, van Beveren NJ, Birnbaum ML, et al. Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology. American Journal of Psychiatry 2017; Vol. 174, issue 3:216-29.

Hutton 2009

Hutton JL. Number needed to treat and number needed to harm are not the best way to report and assess the results

of randomised clinical trials. *British Journal of Haematology* 2009;**146**(1):27-30.

Jäger 2007

Jäger M, Riedel M, Messer T, Laux G, Pfeiffer H, Naber D, et al. Psychopathological characteristics and treatment response of first episode compared with multiple episode schizophrenic disorders. *European Archives of Psychiatry and Clinical Neuroscience* 2007;**257**(1):47-53.

Kane 1996

Kane JM. Pharmacologic treatment of schizophrenia. *Biological Psychiatry* 1999;**46**(10):1396–408.

Kane 2003

Kane JM, Leucht S, Carpenter D, Docherty JP, Expert Consensus Panel for Optimizing Pharmacologic Treatment of Psychotic Disorders. The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary. *Journal of Clinical Psychiatry* 2003;**64**(Suppl 12):5-19.

Kay 1986

Kay SR, Opler LA, Fiszbein A. Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda, NY: Multi-Health Systems, 1986.

Kinon 2004

Kinon BJ, Ahl J, Stauffer VL, Hill AL, Buckley PF. Dose response and atypical antipsychotics in schizophrenia. *CNS Drugs* 2004;**18**(9):597-616.

Lehmann 2004

Lehman AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL, Perkins DO, et al. Practice guideline for the treatment of patients with schizophrenia, second edition. *American Journal* of *Psychiatry* 2004;**161**(2 Suppl):1-56.

Leon 2006

Leon AC, Mallinckrodt CH, Chuang-Stein C, Archibald DG, Archer GE, Chartier K. Attrition in randomized controlled clinical trials: methodological issues in psychopharmacology. *Biological Psychiatry* 2006;**59**(11):1001-5. [PUBMED: 16905632]

Leucht 2005a

Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel RR. What does the PANSS mean?. *Schizophrenia Research* 2005;**79**(2-3):231-8. [PUBMED: 15982856]

Leucht 2005b

Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R. Clinical implications of brief psychiatric rating scale scores. *British Journal of Psychiatry* 2005;**187**:366-71. [PUBMED: 16199797]

Leucht 2007

Leucht S, Engel RR, Bauml J, Davis JM. Is the superior efficacy of new generation antipsychotics an artifact of LOCF?. *Schizophrenia Bulletin* 2007;**33**(1):183-91. [PUBMED: 16905632]



Leucht 2013

Leucht S, Heres S, Kissling W, Davis JM. Pharmacological treatment of schizophrenia. *Fortschritte der Neurologie-Psychiatrie* 2013;**81**:e1-13.

Leucht 2015

Leucht S, Winter-van Rossum I, Heres S, Arango C, Fleischhacker WW, Glenthøj B, et al. The optimization of treatment and management of schizophrenia in Europe (OPTIMISE) trial: rationale for its methodology and a review of the effectiveness of switching antipsychotics. *Schizophrenia Bulletin* 2015;**41**(3):549-58.

Lieberman 2005

Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. *New England Journal of Medicine* 2005;**353**(12):1209–23.

Marshall 2000

Marshall M, Lockwood A, Bradley C, Adams C, Joy C, Fenton M. Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. *British Journal of Psychiatry* 2000;**176**:249-52.

Miller 2009

Miller R. Mechanisms of action of antipsychotic drugs of different classes, refractoriness to therapeutic effects of classical neuroleptics, and individual variation in sensitivity to their actions: Part I. *Current Neuropharmacology* 2009;**7**(4):302-14.

Moher 2001

Moher D, Schulz KF, Altman D. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. *Journal of the American Medical Association* 2001;**285**:1987-1.

Moher 2012

Moher D, Hopewell S, Schulz KF, Montori V, Gøtzsche PC, Devereaux PJ, et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. *International Journal of Surgery (London, England)* 2012;**10**(1):28-55.

Overall 1962

Overall JE, Gorham DR. The brief psychiatric rating scale. *Psychological Reports* 1962;**10**:799-812.

Palmer 2005

Palmer BA, Pankratz VS, Bostwick JM. The lifetime risk of suicide in schizophrenia: a reexamination. *Archives of General Psychiatry* 2005;**62**(3):247-53.

Samara 2015

Samara MT, Leucht C, Leeflang MM, Anghelescu IG, Chung YC, Crespo-Facorro B, et al. Early improvement as a Predictor of later response to antipsychotics in schizophrenia: a diagnostic test review. *American Journal of Psychiatry* 2015;**172**(7):617-29.

Schünemann 2011

Schünemann HJ, Oxman AD, Vist GE, Higgins JP, Deeks JJ, Glasziou P, et al. Chapter 12: Interpreting results and drawing conclusions. In Higgins JP, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.

Simpson 1970

Simpson M, Angus JW. A rating scale for extrapyramidal side effects. *Acta Psychiatrica Scandinavica* 1970;**212**:11-9.

Steijns 1998

Steijns LSW, van der Weide J. Ultrarapid drug metabolism: PCRbased detection of CYP2D6 gene duplication. *Clinical Chemistry* 1998;**44**(5):914-7.

Sterne 2011

Sterne JA, Egger M, Moher D. Chapter 10: Addressing reporting biases. In: Higgins JP, Green S editor(s). Cochrane Handbook for Systematic Reviews of Intervention. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.

Ukoumunne 1999

Ukoumunne OC, Gulliford MC, Chinn S, Sterne JA, Burney PG. Methods for evaluating area-wide and organistation-based intervention in health and health care: a systematic review. *Health Technology Assessment* 1999;**3**(5):1-75.

Vijayan 2012

Vijayan NN, Mathew A, Balan S, Natarajan C, Nair CM, Allencherry PM, et al. Antipsychotic drug dosage and therapeutic response in schizophrenia is influenced by ABCB1 genotypes: a study from a south Indian perspective. *Pharmacogenomics* 2012;**13**(10):1119-27.

Vos 2012

Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. *Lancet* 2012;**380**(9859):2163-96.

Xia 2010

Xia J, Adams CE, Bhagat N, Bhagat V, Bhoopathi P, El-Sayeh H, et al. Loss to outcomes stakeholder survey: the LOSS study. Schizophrenia Research. 2010; Vol. 117, issue 2-3:278.

Zhang 2010

Zhang JP, Lencz T, Malhotra AK. D2 receptor genetic variation and clinical response to antipsychotic drug treatment: a metaanalysis. *American Journal of Psychiatry* 2010;**167**(7):763-72.

References to other published versions of this review

Samara 2015a

Samara MT, Helfer B, Rothe PH, Leucht S. Increasing antipsychotic dose versus switching antipsychotic for non



* Indicates the major publication for the study

response in schizophrenia. *Cochrane Database of Systematic Reviews* 2015, Issue 10. [DOI: 10.1002/14651858.CD011884]

CHARACTERISTICS OF STUDIES

Characteristics of included studies [ordered by study ID]

Methods	Randomisation: randomised Blinding: double, no further details. Duration: 8 weeks; 4 weeks non-randomised open-label run-in phase and 4 weeks randomised dou- ble-blind phase. Design: parallel. Location: single-centre (USA). Setting: inpatients.					
Participants	 Diagnosis: schizophrenia, schizoaffective disorder or schizophreniform disorder (DSM-III-R). 58 participants entered the double-blind phase, but only 29 participants were of interest for the p pose of the present review*. Sex: 64.1% males (for participants entering open label run-in phase (N = 156)), not indicated for ra domised participants. Age: mean 29.4 years (SD = 7.0), range 18 to 50 years for all participants entering the open label ru phase (N = 156), not indicated for randomised participants. History: age at first hospitalisation – mean 23.0 years (SD = 6.5); number of previous hospitalisatio mean 2.6 (SD = 2.2); data for all participants entering the open label run-in phase (N = 156), not indicated participants alone. 					
Interventions	 Antipsychotic dose increase: fluphenazine 80 mg/day. N = 16*. Antipsychotic switching: haloperidol 20 mg/day. N = 13*. Antipsychotic dose maintenance: fluphenazine 20 mg/day. N = 18*. Rescue medication: benztropine, no further details. 					
Outcomes	Global state: clinically relevant response (defined as CGI-I ≤ 2 = at least much improved). Mental state: overall mental state (BRPS total score), negative symptoms (modified SANS). Unable to use: Adverse effects: extrapyramidal symptoms (modified SAS, no mean).					
Notes	*58 non-responders entered the double-blind phase and were randomised to the three treatment op- tions (fluphenazine 20 mg/day, fluphenazine 80 mg/day and haloperidol 20 mg/day). Data were pre- sented for 47 of 58 initially randomised participants (fluphenazine 20 mg/day, N = 18; fluphenazine 80 mg/day, N = 16; and haloperidol 20 mg/day, N = 13). For the purpose of the review, we were interested in the comparison between fluphenazine 80 mg/day, N = 16 and haloperidol 20 mg/day, N = 13; i.e. 29 participants in total.					
Risk of bias						
Bias	Authors' judgement	Support for judgement				
Random sequence genera- tion (selection bias)	Unclear risk	"Nonresponders were then randomly assigned to double-blind treatment for", "Subjects were stratified based on Week 3 serum fluphenazine levels" (p. 310); no further details.				



Kinon 1993 (Continued)

Allocation concealment (selection bias)	Unclear risk	No details were presented.
Blinding of participants and personnel (perfor- mance bias) All outcomes	Unclear risk	"double-blind treatment" (p. 310); no further details.
Blinding of outcome as- sessment (detection bias) All outcomes	Unclear risk	"double-blind treatment" (p. 310); no further details.
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Outcome not addressed. Data were presented for 81% (47/58) of all ran- domised participants.
Selective reporting (re- porting bias)	High risk	SAS was used but scores were available only for two items, not total.
Other bias	Low risk	No obvious risk for other bias.

Scales

BPRS: Brief Psychiatric Rating Scale

CGI-I: Clinical Global impression-Improvement

SANS: Scale for the Assessment of Negative Symptoms

SAS: Simpson Angus Scale

Diagnostic Tools

DSM-III-R: Diagnostic and Statistical Manual of Mental Disorders, third edition, revised

Others

mg: milligram

N: number

SD: standard deviation

Characteristics of excluded studies [ordered by study ID]

Study	Reason for exclusion
Agid 2013	Allocation: not randomised
Bondolfi 1995	Allocation: randomised, no further details Participants: schizophrenia, treatment-resistant (defined by unresponsiveness or intolerance to appropriate doses of 2 different classes of conventional antipsychotics for at least 4 weeks each); no run-in phase to confirm that participants have not responded to their current antipsychotic treatment. Interventions: risperidone versus clozapine; no antipsychotic dose increase versus antipsychotic switching group comparison; drug dosages could be changed after day 14 depending on each par- ticipant's response.

Cochrane Library

Study	Reason for exclusion
Buckley 1995	Allocation: not indicated Participants: people with schizophrenia whose baseline clozapine concentrations fell below 370 ng/ml. Interventions: clozapine dose increase versus maintenance; no antipsychotic switching group.
Conley 2003	Allocation: randomised, no further details Participants: were eligible if they met criteria for treatment resistance; all receiving conventional antipsychotics, risperidone or olanzapine prior to study initiation. Interventions: olanzapine versus clozapine; no antipsychotic dose increase versus antipsychotic switching group comparison.
Dunn 2005	Allocation: double-blind phase: randomised; open-label phase: not randomised. Participants: were eligible if they had received haloperidol for 6 weeks and showed lack of re- sponse. Interventions: double-blind phase: no antipsychotic dose increase group; open-label phase: no comparison, only ziprasidone was administered.
Ganguli 2003	Allocation: randomised, no further details Participants: were eligible due to tolerability issues as well; not only non-responders. Interventions: 3 switching paradigms; no dose increase group
Goff 2013	Allocation: randomised, no further details Participants: were eligible if they had firstly received open-label ziprasidone treatment, titrated up to 160 mg/day, for a minimum of 3 weeks and had persistent psychotic symptoms defined by a score of 4 (moderate) or greater on any item of PANSS. Interventions: ziprasidone dose increase versus ziprasidone dose maintenance; no antipsychotic switching group.
Harvey 2007	Allocation: randomised, no further details Participants: were eligible due to tolerability issues as well; not only non-responders. Interventions: clozapine versus ziprasidone; no dose increase group.
Hatta 2012	Allocation: randomised and concealed; "a random number table", "sequentially numbered, opaque, sealed envelopes" (p. 195). Participants: were eligible if they had firstly received flexible-dose oral risperidone treatment for 2 weeks and were considered to be non-responders according to the Clinical Global Impressions-Im provement scale (a score of 4 or higher). Interventions: risperidone dose increase versus risperidone augmented with olanzapine; no an- tipsychotic switching group.
Honer 2010	Allocation: randomised and concealed; "with a computerized schedule", "the person who generat ed the randomization schedule was not involved in determining subject eligibility, administering treatment, or determining outcome" (p. 14). Participants: were eligible if they had firstly received open-label quetiapine treatment of 800 mg/ day for 4 weeks and had persistent positive and negative symptoms and a rating in the Clinical Global Impressions scale of at least 4. Interventions: quetiapine dose increase versus quetiapine dose maintenance; no antipsychotic switching group.
Janicak 1994	Allocation: randomised, no further details Participants: acutely psychotic (primarily people with schizophrenia) that were non-responders to haloperidol treatment for 2 weeks. Interventions: low versus middle versus high haloperidol plasma level; no antipsychotic switching group.
Kane 1988	Allocation: randomised, no further details Participants: were eligible if they had firstly received single-blind flexible haloperidol treatment (up to 60 mg/day or higher) for 6 weeks and were considered to be non-responders.

Copyright @ 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Study	Reason for exclusion					
	Interventions: clozapine versus chlorpromazine; no antipsychotic dose increase group.					
Kane 2007	Allocation: randomised, no further details. Participants: were eligible if they had received at least 15 mg/day olanzapine or 6 mg/day risperi- done for a minimum of 3 weeks and showed no significant improvement. Interventions: aripiprazole versus perphenazine; no antipsychotic dose increase group.					
Kim 2013	Allocation: not randomised.					
Kinon 2010	Allocation: randomised and concealed; "interactive voice response system", "the precise response criterion was withheld from research staff but defined a priori in the Institutional Review Board (IRB) Supplement, and early responder/non-responder status was identified and treatment ran- domization was implemented using an interactive voice response (IVR) system" (p583). Participants: were eligible if they had received single-blind (i.e. to dose and dose adjustments), flexible-dose therapy with risperidone 2 mg/day to 6 mg/day for 2 weeks and did not respond to treatment. Interventions: risperidone versus olanzapine; no antipsychotic dose increase group.					
Lindenmayer 2011	Allocation: randomised, no further details Participants: were eligible if they had firstly received open label quetiapine 600 mg/day for 4 weeks and did not demonstrate an initial response defined as ≤ 15% PANSS total score reduction. Interventions: quetiapine 600 mg/day versus 1200 mg/day; no antipsychotic switching group.					
McEvoy 2013	Allocation: randomised, no further details. Participants: non-acute patients appropriate for switching current antipsychotic medication; not indicated if they were non-responders. Interventions: 3 switching strategies to lurasidone; no antipsychotic dose increase group.					
NCT00161018	Allocation: randomised, no further details. Participants: optimised with routine antipsychotic treatment for 4 to 6 weeks to prospectively es- tablish lack of response to conventional antipsychotic therapy. Interventions: lack of response to 4 to 6 weeks' conventional antipsychotic therapy, then randomi sation to quetiapine, risperidone or fluphenazine; no antipsychotic dose increase group.					
NCT00191555	Allocation: randomised, no further details. Participants: were eligible due to tolerability issues as well; not only non-responders.					
Potkin 1994	Allocation: randomised, no further details. Participants: were eligible if they were judged to be non-responders to conventional antipsy- chotics. Interventions: randomised to clozapine 400 mg/day or 800 md/day; no antipsychotic switching group.					
Sacchetti 2009	Allocation: randomised; "randomised on a centralized basis" (p. 82). Participants: were eligible due to lack of tolerance as well; not only non-responders. Interventions: ziprasidone versus clozapine; no antipsychotic dose increase group.					
Simpson 1999	Allocation: randomised, no further details. Participants: people with treatment refractory symptoms of schizophrenia. Interventions: clozapine 100, 300 or 600 mg/day; if no improvement was observed after 16 weeks, participants were randomised to one of the other two dosages, no switching group.					
Suzuki 2007	Allocation: not randomised; randomisation to treatment algorithms, switching of all non-respon- ders.					
Weiden 2003	Allocation: randomised, no further details Participants: stable outpatients with persistent symptoms or troublesome side effects; not non-re sponders.					

Study	Reason for exclusion
	Interventions: 3 switching strategies to ziprasidone; no antipsychotic dose increase group.
Wirshing 1999	Allocation: randomised; "a computerized random-number-generating program" (p. 1375). Participants: were eligible due to lack of tolerance as well; not only non-responders. Interventions: risperidone versus haloperidol; no antipsychotic dose increase group.

DATA AND ANALYSES

Comparison 1. Increasing the antipsychotic dose versus switching the atipsychotic drug

Outcome or subgroup title	No. of studies	No. of partici- pants	Statistical method	Effect size
1 Global state: clinically relevant response – as defined by trial	1	29	Risk Ratio (M-H, Ran- dom, 95% CI)	1.63 [0.17, 15.99]
2 Mental state: general mental state - aver- age endpoint score (BPRS total, high =poor)	1	29	Mean Difference (IV, Random, 95% CI)	2.0 [-4.20, 8.20]
3 Mental state: negative symptoms - average endpoint score (SANS, high = poor)	1	29	Mean Difference (IV, Random, 95% CI)	3.40 [-12.56, 19.36]

Analysis 1.1. Comparison 1 Increasing the antipsychotic dose versus switching the atipsychotic drug, Outcome 1 Global state: clinically relevant response – as defined by trial.

Study or subgroup	Dose increase	Switching			Risk Ratio			Weight	Risk Ratio
	n/N	n/N		м-н,	Random, 95º	% CI			M-H, Random, 95% CI
Kinon 1993	2/16	1/13						100%	1.63[0.17,15.99]
Total (95% CI)	16	13						100%	1.63[0.17,15.99]
Total events: 2 (Dose increase),	1 (Switching)								
Heterogeneity: Not applicable									
Test for overall effect: Z=0.42(P=	=0.68)		_						
		avours switching	0.05	0.2	1	5	20	Favours dose increase	2

Analysis 1.2. Comparison 1 Increasing the antipsychotic dose versus switching the atipsychotic drug,

Outcome 2 Mental state: general mental state - average endpoint score (BPRS total, high =poor).

Study or subgroup	Dose	e increase	Sw	vitching	Mean Difference	Weight	Mean Difference
	N	Mean(SD)	Ν	Mean(SD)	Random, 95% CI		Random, 95% Cl
Kinon 1993	16	40.2 (10.4)	13	38.2 (6.5)		100%	2[-4.2,8.2]
Total ***	16		13			100%	2[-4.2,8.2]
Heterogeneity: Not applicable							
			Favours	dose increase	-10 -5 0 5 10	Favours swit	ching



Study or subgroup	Dose increase		Switching		Mean Difference			Weight	Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	Rando	om, 95% (CI		Random, 95% CI
Test for overall effect: Z=0.63(P=0.53)							1		
			Favours	dose increase	-10 -5	0 5	10	Favours swi	tching

Analysis 1.3. Comparison 1 Increasing the antipsychotic dose versus switching the atipsychotic drug, Outcome 3 Mental state: negative symptoms - average endpoint score (SANS, high = poor).

Study or subgroup	Dose	e increase	Sw	/itching	Mean Difference	Weight	Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	Random, 95% CI		Random, 95% Cl
Kinon 1993	16	55.5 (26)	13	52.1 (17.7)		100%	3.4[-12.56,19.36]
Total ***	16		13			100%	3.4[-12.56,19.36]
Heterogeneity: Not applicable							
Test for overall effect: Z=0.42(P=0.68)						
			Favours	dose increase	-10 -5 0 5 10	Favours swi	itching

ADDITIONAL TABLES

Table 1. Suggested design for future study

Randomisation: random Allocation: concealed Blinding: double blind Duration: at least 2 weeks run-in phase to confirm non response to initial treatment and at least 4 weeks' randomised double-blind phase. Setting: in- or out-patients
Diagnosis: people with schizophrenia, schizoaffective disorder or schizophreniform disorder N > 450 Gender: male and female Age: mean 30 years (SD = 7.0), range 18 to 65 years
All participants firstly receive treatment with one antipsychotic drug for at least 2 weeks. Those participants who do not at least minimally improve after 2 weeks, are considered non-responders and are randomised to: 1. increasing the dose of the initial antipsychotic drug above the officially recommended dose range; or 2. switching the initial antipsychotic drug to another one with a different receptor profile; or 3. continuing treatment with the initial antipsychotic drug and at the same, initial dose (within the
officially recommended dose range)
Leaving the study early due to any reason Leaving the study early due to side effects General mental state: average change in general mental state scores

Table 1. Suggested design for future study (Continued)

Adverse effects: at least one adverse effect; clinically important general adverse effects; sudden and unexpected death

Service use: time in hospital

Quality of life

All outcomes by time – short term (up to 12 weeks), medium term (13 to 26 weeks) and long term (over 26 weeks)

Notes

*Primary outcome of interest

APPENDICES

Appendix 1. Previous searches

Search in 2014 and 2015

Electronic searches

1. Cochrane Schizophrenia Group's Trials Register

On 10 June 2014 and 6 October 2015, the Trials Search Co-ordinator (TSC) of the Cochrane Schizophrenia Group searched the Group's Registry of Trials using the following search strategies which have been developed based on literature review and consulting the authors of the review:

((("non respon*" or nonrespon* or "not respon*" or "no respon*" or unrespon* or fail* or unsuccess* or *resist* or persist* or residual or untreat* or refract* or ineffective or "not effective" or unchanged) or ((drug* or therap* or treat* or antipsychotic* or neuroleptic* or tranquili* or partial* or incomplete*) NEXT respon*) or ((poor or subsequen*) NEAR3 respon*)) and (((shift* or chang* or cross* or *taper* or overlap* or stay* or *continu* or remain* or combin* or ongoing or "on going") or switch*) and (dose* or dosage* or dosing))):ti,ab of REFERENCE or ((switch* or shift* or chang* or cross* or *taper* or overlap* or stay* or *continu* or remain* or combin* or ongoing or "on going") and (dose* or dosage* or dosing)):sin of STUDY.

The Cochrane Schizophrenia Group's Registry of Trials is compiled by systematic searches of major resources (including AMED, BIOSIS, CINAHL, Embase, MEDLINE, PsycINFO, PubMed, and registries of clinical trials) and their monthly updates, handsearches, grey literature, and conference proceedings (see Group Module). There is no language, date, document type, or publication status limitations for inclusion of records into the register.

Searching other resources

1. Reference searching

We inspected references of all included studies for further relevant studies.

2. Personal contact

We contacted the first author of each included study for information regarding unpublished trials.

CONTRIBUTIONS OF AUTHORS

Myrto Samara: protocol development, study selection, data extraction, writing the report.

Elisabeth Klupp: study selection, data extraction.

Bartosz Helfer: protocol development.

Philipp Rothe: protocol development.

Johannes Schneider-Thoma: writing of a summary report for the review.

Stefan Leucht: protocol development, study selection, data extraction, writing the report.



DECLARATIONS OF INTEREST

Myrto Samara: none known.

Elisabeth Klupp: none known.

Bartosz Helfer: none known.

Philipp Rothe: none known.

Johannes Schneider-Thoma: none known.

Stefan Leucht - has received honoraria for consulting from LB Pharma, Lundbeck, Otsuka, TEVA, Geodon Richter, Recordati, LTS Lohmann, and Boehringer Ingelheim; and for lectures from Janssen, Lilly, Lundbeck, Otsuka, SanofiAventis, and Servier.

SOURCES OF SUPPORT

Internal sources

• Klinik und Poliklinik für Psychiatrie und Psychotherapie, Technische Universität München Klinikum rechts der Isar, München, Germany.

Employs review authors Myrto T Samara, Bartosz Helfer, Philipp H Rothe, Johannes Schneider-Thoma and Stefan Leucht.

External sources

• Bundesministerium für Bildung und Forschung (BMBF), Germany.

Grant number: FKZ 01KG1407

DIFFERENCES BETWEEN PROTOCOL AND REVIEW

We have removed the second sentence from Objectives ("We will include any antipsychotic drug studies in any people with schizophrenia, however diagnosed") as this is also described in Types of participants.

We have renamed outcomes from 'Clinically significant response' to 'Clinically important change'.

We have now specified 'Summary of findings' table outcomes should be 'Clinically important change' but if data were not available for these pre-specified outcomes but were available for ones that are similar, we presented the closest outcome to the pre-specified one in the table but took this into account when grading the finding.

We have updated the methods template to the latest version provided by Cochrane Schizophrenia. This does not involve a change to the methods but updating of references and rewording of some sections.

We have reworded some of the background to harmonise this review with its 'sibling review' Helfer 2015

INDEX TERMS

Medical Subject Headings (MeSH)

*Drug Substitution; Antipsychotic Agents [*administration & dosage]; Fluphenazine [*administration & dosage]; Haloperidol [*administration & dosage]; Schizophrenia [drug therapy]; Treatment Outcome

MeSH check words

Humans